| Stereochemistry | UNKNOWN |
| Molecular Formula | C19H23NO |
| Molecular Weight | 281.392 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C(O)C1=CC=CC=C1)N(C)C\C=C\C2=CC=CC=C2
InChI
InChIKey=YMJMZFPZRVMNCH-FMIVXFBMSA-N
InChI=1S/C19H23NO/c1-16(19(21)18-13-7-4-8-14-18)20(2)15-9-12-17-10-5-3-6-11-17/h3-14,16,19,21H,15H2,1-2H3/b12-9+
| Molecular Formula | C19H23NO |
| Molecular Weight | 281.392 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Approval Year
PubMed
Patents
Sample Use Guides
Midol (a combination of cinnamedrine hydrochloride, aspirin, phenacetin, and caffeine) - two tablets every four hours, with a maximum eight tablets per day.
Route of Administration:
Oral
It was examined influence of cinnamedrine on the smooth muscle relaxing properties using rat uterus. Cinnamedrine exhibited dose-related spasmolytic activity in the isolated spontaneously contracting rat uterus and in uterine tissue pretreated with oxytocin to augment spasms. The IC50's for cinnamedrine was 36.2 microM; the IC50's after oxytocin pretreatment was 25.7 microM for cinnamedrine.
